Drugs / andrographolide
andrographolide
Trials 5
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/21 trial · 1 missed | ||||||
| Phase 1/2 | NCT02273635 | Sep 2014 → Nov 2016 | primary progressive multiple sclerosis, secondary progressive multiple sclerosis | Innobioscience SpA | Unknown | Missed primary |
| Phase 22 trials | ||||||
| Phase 2 | NCT00659802 | Feb 2008 → Oct 2009 | ulcerative colitis | Hutchison Medipharma Limited | Completed | No outcome recorded |
| Phase 2 | NCT00655733 | Apr 2006 → Apr 2009 | Crohn disease | Hutchison Medipharma Limited | Completed | No outcome recorded |
| Phase 32 trials · 1 missed | ||||||
| Phase 3 | NCT01882764 | Jun 2013 → Oct 2014 | ulcerative colitis | Hutchison Medipharma Limited | Terminated | No outcome recorded |
| Phase 3 | NCT01805791 | Mar 2013 → Oct 2014 | ulcerative colitis | Hutchison Medipharma Limited | Terminated | Missed primary |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2014-08-13 | Hutchison Medipharma Limited | Results HMPL-004 NATRUL-3 interim analysis result hutch-med.com ↗
An independent Data Safety and Monitoring Committee (“DSMC”) evaluated the unblinded data of two doses of HMPL-004 vs. placebo, and has recommended that NSP terminate the study. |
All press releases naming this drug 3 releases
| Date | Issuer | Release |
|---|---|---|
| 2014-08-13 | Hutchison Medipharma Limited | HMPL-004 NATRUL-3 interim analysis result hutch-med.com ↗ |
| 2013-07-17 | Hutchison Medipharma Limited | Nutrition Science Partners announces initiation of NATRUL-4, the maintenance study of the global Phase III trial for HMPL-004 hutch-med.com ↗ |
| 2013-04-24 | Hutchison Medipharma Limited | Nutrition Science Partners announces initiation and treatment of the first Ulcerative Colitis patient in the global NATRUL Phase III trial for the novel botanical oral drug HMPL-004 hutch-med.com ↗ |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 6 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | andrographolide | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02273635 ↗ |
| Known as | HMPL-004 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00659802 ↗ |
| Known as | NSC-383468 | ChEMBL registry synonym — accepted as the source's own label CHEMBL186141 ↗ |
| Modality | Small molecule | — CHEMBL186141 ↗ |
| Route | Oral | “oral HMPL-004” NCT00655733 ↗ |